Live Breaking News & Updates on Euronext Nasdaq

Stay updated with breaking news from Euronext nasdaq. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq

Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced ....

Mont Saint Guibert , Waals Gewest , United States , New York , Caroline Lonez , David Georges , Us Securities Exchange , Exchange Commission , Business Development , Company Adss , Company On , Wrd Communications , Adss Of The Company , Regulatory News , Euronext Nasdaq , American Depositary Shares , Nasdaq Global Market , American Depositary Receipt , Nasdaq Stock Market , Nasdaq Listing Rule , Exchange Act , Celyad Oncology , Private Securities Litigation Reform Act , Annual Report , Oncology Contacts ,

Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business Highlights

Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneously Publication of results from the THINK trial, which provided proof-of-concept ....

United States , Mont Saint Guibert , Waals Gewest , New York , David Georges , Georges Rawadi , Caroline Lonez , International Convention , Business Development , Exchange Commission , World Oncology Cell Therapy Congress , Wrd Communications , Euronext Nasdaq , Chief Executive Officer , Lancet Haematology , Private Securities Litigation Reform Act , Celyad Oncology , Annual Report , Oncology Contacts ,

Celyad Oncology SA: Celyad Oncology Announces Receipt of Nasdaq Initial Notification on ADS Bid Price

Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received ....

United States , New York , Mont Saint Guibert , Waals Gewest , Caroline Lonez , David Georges , Company Adss , Wrd Communications , Stockholder Equity Notice For The Company , Company Form , Exchange Commission , Business Development , Regulatory News , Euronext Nasdaq , Nasdaq Stock Market , American Depositary Shares , Nasdaq Listing Rule , Bid Price , Bid Price Notice , Nasdaq Global , Minimum Bid Price , Compliance Date , Nasdaq Capital Market , Minimum Bid Price Requirement , Nasdaq Global Market , Stockholder Equity ,

Celyad Oncology announces receipt of Nasdaq notice

Celyad Oncology announces receipt of Nasdaq notice
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New York , United States , Mont Saint Guibert , Waals Gewest , David Georges , Caroline Lonez , Company American Depositary , Wrd Communications , Company Form , Letter For The Company , Business Development , Exchange Commission , Regulatory News , Euronext Nasdaq , Nasdaq Stock Market , Nasdaq Listing Rule , Nasdaq Global Market , Stockholder Equity , American Depositary Shares , Private Securities Litigation Reform Act , Celyad Oncology , Annual Report ,

Celyad Oncology SA: Celyad Oncology Appoints Georges Rawadi as Its New CEO

Regulatory News: Celyad Oncology (Euronext Nasdaq: CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased ....

Mont Saint Guibert , Waals Gewest , New York , United States , Michel Lussier , Hilde Windels , Georges Rawadi , Caroline Lonez , David Georges , Business Development , Exchange Commission , Health Industry , Wrd Communications , Business Development Intellectual Property , Business Development Of Cellectis France Nasdaq , Regulatory News , Euronext Nasdaq , Chief Executive Officer , Celyad Oncology , Ysopia Bioscience , Vice President Business Development , France Nasdaq , Master Degree , Executive Master , Private Securities Litigation Reform Act , Annual Report ,